Search

Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality in the Western world. However, emerging treatment options and more patients directed to active treatments might improve the outcomes. Here, we retrospectively studied the patient characteristics and treatment practices for NSCLC in Finland 2014-2019 with a special focus on changes in trends over time.The cohort consisted of patients diagnosed with NSCLC in Finland 2014-2018. Cancer treatments for the patients were followed until the end of 2019. The data, both structured and unstructured, were collected from electronic medical records of four university hospitals in Finland.Of the study population (The current study suggests a trend in NSCLC towards more active treatment approaches in 2014-18.

e18806 Background: Ovarian cancer (OC) is a disease characterized by a dynamic treatment landscape in the real-life setting. The OCRWE-Finland study aims at describing the real-life burden of patients with OC, including treatment patterns, time to next treatment, disease characteristics and progression, survival, and healthcare resource utilization. This abstract reports on the observed treatment patterns. Methods: OCRWE-Finland is a multicenter, retrospective, noninterventional study collecting hospital medical records from the university hospitals in Helsinki, Turku, and Tampere. Patients with ovarian, fallopian tube, or primary peritoneal cancer who were newly diagnosed as part of routine clinical care and who received all their OC treatments in these university hospitals during the period 2014-2019 were included, covering about 50% of the Finnish OC care patients. Registry data were collected and combined by Findata (authorization holder), which operates under the performance guidance of the Finnish Ministry of Social Affairs and Health. Results: In total, 1711 patients with OC (mean age = 65.9 y, SD = 13.4 y) and 621 patients with high-grade serous OC (HGSOC) (mean age = 68.0 y, SD = 10.1 y) were identified. Initial diagnosis assumed the origin of the disease was the ovaries in 75% of patients and the peritoneum in 19%. Of the patients with HGSOC, 55% had FIGO stage III disease and 20% stage IV at diagnosis; 5% had stage II and 9% stage I. For 11%, no data of the FIGO stage at diagnosis were found in text mining. 59% of the HGSOC patients were treated with primary debulking surgery (PDS), 21% with neoadjuvant chemotherapy (CT) and interval debulking surgery, and 12% with only CT in first-line treatment (TL1). Among patients with stage I-IV HGSOC who underwent PDS, the disease was optimally debulked in 37% of the patients and suboptimally debulked in 44% (Residual < 1 cm in 27%, Residual≥1 cm in 17%). Residual tumor status was unknown for 19%. During the observation period, 57% of patients received a TL2, and 48% of these patients moved to TL3. The probability of undergoing a TL2 was higher among stage III/IV patients and among patients with residual disease. In TL2, the most common treatment was platinum-based CT (32%), and “other CT” was administered in 26% of cases; 33% of patients did not receive any TL2 during the observation period but were still alive, and 9% died before initiating TL2. Conclusions: This study documents real-life treatment patterns across lines of treatment among patients with OC and HGSOC during the first years of disease from the three biggest university hospitals in Finland. These results can provide useful baseline information about the rapidly evolving treatment landscape in OC in recent years.